Huang et al. [103] reported the use of PASS web resources for the validation of MYC/CXCL8 (C-X-C motif chemokine ligand 8)/TIMP1 (TIMP metallopeptidase inhibitor 1) oncogenes, which regulate immune response in an antitumor direction by mediating PD-L1, as potential drug targets for RV59 (57), an anthraquinone derivative with anticancer activity against NCI human colon cancer cell lines (Figure 13). This evidence concerns the gene CXCL8 and malignant colon neoplasm.